Top

Published in:

Open Access 01-12-2016 | Case Report

Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma

Authors: Phedias Diamandis, Ruben Ferrer-Luna, Raymond Y. Huang, Rebecca D. Folkerth, Azra H. Ligon, Patrick Y. Wen, Rameen Beroukhim, Keith L. Ligon, Shakti H. Ramkissoon

Published in: Diagnostic Pathology | Issue 1/2016

Abstract

Background

Molecular profiling has uncovered genetic subtypes of glioblastoma (GBM), including tumors with IDH1 mutations that confer increase survival and improved response to standard-of-care therapies. By mapping the genetic landscape of brain tumors in routine clinical practice, we enable rapid identification of targetable genetic alterations.

Case Presentation

A 29-year-old male presented with new onset seizures prompting neuroimaging studies, which revealed an enhancing 5 cm intra-axial lesion involving the right parietal lobe. He underwent a subtotal resection and pathologic examination revealed glioblastoma with mitoses, microvascular proliferation and necrosis. Immunohistochemical (IHC) analysis showed diffuse expression of GFAP, OLIG2 and SOX2 consistent with a tumor of glial lineage. Tumor cells were positive for IDH1(R132H) and negative for ATRX. Clinical targeted-exome sequencing (DFBWCC Oncopanel) identified multiple functional variants including IDH1 (p.R132H), TP53 (p.Y126_splice), ATRX (p.R1302fs*), HNF1A (p.R263H) and NF1 (p.H2592del) variants and a NAB2-STAT6 gene fusion event involving NAB2 exon 3 and STAT6 exon 18. Array comparative genomic hybridization (aCGH) further revealed a focal amplification of NAB2 and STAT6. IHC analysis demonstrated strong heterogenous STAT6 nuclear localization (in 20 % of tumor cells).

Conclusions

While NAB2:STAT6 fusions are common in solitary fibrous tumors (SFT), we report this event for the first time in a newly diagnosed, secondary-type GBM or any other non-SFT. Our study further highlights the value of comprehensive genomic analyses in identifying patient-specific targetable mutations and rearrangements.

Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107:359–64. doi:10.1007/s11060-011-0749-4.CrossRefPubMed

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707–18. doi:10.1007/s00401-010-0781-z.CrossRefPubMed

Hegi ME, Diserens A-C, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005;352:997–1003. doi:10.1056/NEJMoa043331.CrossRefPubMed

Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011;6:e17948. doi:10.1371/journal.pone.0017948.PubMedCentralCrossRefPubMed

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, Aldape KD, Yung WK, Salama SR et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372:2481–98. doi:10.1056/NEJMoa1402121.CrossRef

Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2:82–93. doi:10.1158/2159-8290.CD-11-0184.PubMedCentralCrossRefPubMed

Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, et al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro. Oncol. 2015;17:1344–1355. doi:10.1093/neuonc/nov015.CrossRefPubMed

Robinson DR, Wu Y-M, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat. Genet. 2013;45:180–5. doi:10.1038/ng.2509.PubMedCentralCrossRefPubMed

Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125:651–8. doi:10.1007/s00401-013-1117-6.CrossRefPubMed

10.

Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget 2014;5:8083–92.PubMedCentralCrossRefPubMed

11.

Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat. Genet. 2013;45:131–2. doi:10.1038/ng.2522.PubMedCentralCrossRefPubMed

12.

Frith AE, Hirbe AC, Van Tine BA. Novel pathways and molecular targets for the treatment of sarcoma. Curr Oncol Rep. 2013;15:378–85. doi:10.1007/s11912-013-0319-3.CrossRefPubMed

13.

Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462–77. doi:10.1016/j.cell.2013.09.034.PubMedCentralCrossRefPubMed

14.

Shah N, Lankerovich M, Lee H, Yoon JG, Schroeder B, Foltz G. Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC Genomics. 2013;14:818. doi:10.1186/1471-2164-14-818.PubMedCentralCrossRefPubMed

15.

Weaver J, Downs-Kelly E, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, Rubin BP, Skacel M. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol. 2008;21(8):943-9. doi:10.1038/modpathol.2008.CrossRefPubMed

Title: Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma
Authors: Phedias Diamandis
Ruben Ferrer-Luna
Raymond Y. Huang
Rebecca D. Folkerth
Azra H. Ligon
Patrick Y. Wen
Rameen Beroukhim
Keith L. Ligon
Shakti H. Ramkissoon
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2016
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-016-0455-9

At a glance: The STEP trials

Springer Medicine

Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma

Abstract

Background

Case Presentation

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Case Presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

An unusual case of uterine cotyledonoid dissecting leiomyoma with adenomyosis

Small vessel microembolization and acute glomerulonephritis following infection of aesthetic filler implants

Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis

Retraction Note: High doses of garlic extract significantly attenuated the ratio of serum LDL to HDL level in rat-fed with hypercholesterolemia diet

Low-grade myofibroblastic sarcoma arising in fibroadenoma of the breast-A case report–

Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis